FDA c'ttee recommends expanded indication for FluMist

Anglo-Swedish drug major AstraZeneca says that a US Food and Drug Administration advisory committee has recommended that the nasal influenza vaccine FluMist, produced by its recently purchased US unit MedImmune, be used to protect children aged two and upwards. The guidance, which follows the expansion of the product's indication that the FDA granted last month (Marketletters passim), will be passed on to the Secretary of State for Health and Human Services for a final decision, and inclusion in the nationwide vaccination program.